TESARO, Inc. (TSRO) Now Covered by Analysts at Royal Bank Of Canada
Stock analysts at Royal Bank Of Canada assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a research report issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Monday, June 5th. Cann reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Sunday, June 4th. Bank of America Corporation reiterated a “buy” rating and issued a $154.00 price objective on shares of TESARO in a report on Tuesday, June 20th. Finally, Gabelli initiated coverage on shares of TESARO in a report on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $175.15.
Shares of TESARO (NASDAQ TSRO) traded down 0.34% during trading on Thursday, hitting $115.24. The company’s stock had a trading volume of 620,800 shares. TESARO has a 52 week low of $93.93 and a 52 week high of $192.94. The firm’s 50 day moving average price is $122.82 and its 200-day moving average price is $141.29. The company’s market cap is $6.24 billion.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the firm earned ($1.28) EPS. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. On average, analysts predict that TESARO will post ($8.67) earnings per share for the current year.
In related news, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,100 shares of company stock valued at $3,387,465. Insiders own 40.50% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Vident Investment Advisory LLC bought a new stake in shares of TESARO during the 1st quarter valued at about $351,000. Botty Investors LLC bought a new stake in shares of TESARO during the 2nd quarter valued at about $140,000. Meeder Asset Management Inc. bought a new stake in shares of TESARO during the 1st quarter valued at about $177,000. Nordea Investment Management AB bought a new stake in shares of TESARO during the 2nd quarter valued at about $167,000. Finally, Oppenheimer Asset Management Inc. grew its position in shares of TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.